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Abstract
Permanent prostate brachytherapy has been practiced for more than a century. This review examines the influence
of earlier procedures on the modern transperineal ultrasound-directed technique. A literature review was conducted
to examine the origin of current clinical practice. The dimensions of the modern brachytherapy seed, the prescription
dose, and implant/teletherapy sequencing are vestigial features, which may be suboptimal in the current era of low-
energy photon-emitting radionuclides and computerized dose calculations. Although the modern transperineal permanent
prostate implant procedure has proven to be safe and effective, it should undergo continuous re-evaluation and evo-
lution to ensure that its potential is maximized.
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Purpose
Transrectal ultrasound-guided permanent prostate bra -
chytherapy (PB) was introduced 30 years ago in Denmark,
and there are now mature series demonstrating excellent and
durable disease control [1–3]. Despite advances in radiobio-
logy and technology, the general procedure has changed 
little over the intervening years. Prostate brachytherapy is one
of several choices in the highly-competitive arena of prostate
cancer treatment options, which includes external-beam 
radiotherapy (EBRT), surgery, cryotherapy, and possibly high-
intensity focused ultrasound (HIFU). These treatment
modalities have evolved to reduce toxicity, adopting features
such as image-guidance (EBRT), nerve-sparing (prostatec-
tomy), robotics (prostatectomy), and urethral warming
(cryo therapy). Prostate brachytherapy must also evolve to
remain a vital, relevant, and competitive treatment option.
The American Brachytherapy Society has recently issued
guidelines, based upon current practice, for the ‘safe and ef-
ficient delivery of PB’ [4].
Evolutionary biologists have noted that organisms often
retain vestigial traits that reflect their phylogeny (evolutio -
nary history). Such features may be superfluous or even
detrimental. Similarly, medical procedures can retain ele-
ments of techniques and technology that they have replaced.
We have identified several such features in the modern
prostate brachytherapy procedure.
Seed dimensions
Almost all permanent brachytherapy sources (‘seeds’)
have the same dimensions: 4.5 mm in length and 0.8 mm
in diameter. How did these dimensions originate, and are
they essential to the technique?
Urologists began treating prostate cancer with intra-ure-
thral radium (226Ra) tubes more than a century ago [5, 6].
Temporary interstitial prostate brachytherapy was intro-
duced at New York’s Memorial Hospital in 1915 [7].
Memo rial’s large stock of 226Ra was kept in solution, and
the emitted radon (222Rn) was utilized for treatment [8].
222Rn’s greater specific activity (compared to 226Ra) allowed
use of thinner needles, reducing the trauma of implantation
[9]. Urologist Benjamin Barringer inserted 222Rn needles
through the perineum and into the prostate, where they re-
mained for hours; in this way, he initiated out-patient tem-
porary interstitial PB. By 1920, he attempted permanent im-
plantation using 222Rn in tiny capsules fashioned from glass
capillary tubes [10]. This resulted in painful necrosis, because
the emitted β particles easily traversed the glass, deposit-
ing a destructive dose into immediately adjacent tissue [11].
Physicist Gioacchino Failla tackled this problem by en-
capsulating the 222Rn in gold tubing, rather than glass. In
a series of experiments, he determined that a 0.3 mm thick-
ness of gold would filter 99.6% of the harmful β particles,
but allow passage of 82% of the therapeutic γ rays [11]. These
‘seeds’ were 0.8 mm in width and 4-5 mm in length, and
could pass through an 18-gauge needle. They became quite
popular in the U.S. and were used to implant a wide array
of benign (nevi) and malignant (oral, pharyngeal, bladder,
prostate) tumors. Seed injectors with magazines (i.e.,
‘guns’) were devised for rapid insertion [12]. The use of 222Rn
seeds persisted for decades, the last U.S. manufacturing fa-
cility of 222Rn seeds closed in 1981 [13].
The modern brachytherapy seed was introduced in 1965.
Health physicist Donald Lawrence, in consultation with 
Memorial radiation oncologist Ulrich Henschke, encased
a nylon filament impregnated with 125I inside titanium tub-
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ing [14]. Titanium was preferable to gold, because it trans-
mitted the low-energy γ- and X-rays from 125I (which does
not emit high-energy βparticles). While 0.3mm capsule walls
were no longer needed, Lawrence replicated the 222Rn seed
dimensions to ease transition, but also because he fashioned
the seeds by hand and could not work with smaller tubing
[14]. Multiple manufacturers have since produced iodine
(125I), as well as palladium (103Pd), and cesium (131Cs) seeds.
While surface variations (such as dimpling, to enhance echo -
genicity) have been employed, the seed dimensions have 
essentially been maintained. However, a thinner (0.5 mm
diameter) 125I seed that can pass through a 20-gauge needle
has been introduced [15, 16] and is being evaluated to de-
termine if the smaller puncture would reduce urinary and
sexual toxicity [17]. The optimal design from the perspec-
tive of post-implant dosimetry and localization uncertain-
ties does not appear to have been explored.
Prescription dosing
The recommended 125I monotherapy prescription dose
for a prostate implant is 144 Gy [18-20]; prescription dos-
es for 103Pd and 131Cs implants have been calculated to be
radiobiologically equivalent [21, 22]. But how was the 144Gy
dose derived?
It had been determined by Paterson and Parker in Man-
chester [23] and Quimby in New York [24] that the appro-
priate dose for treating an epithelial tumor with radium nee-
dles was 6,000-8,000 rads delivered over 6-8 days. Quimby
generated tables for determining equivalent radiation ef-
fect between temporary 226Ra (mg-h) and permanent 222Rn
(mCi) implants [25]. The most common permanent implant
performed at Memorial Hospital in the 1950’s was of un-
resectable lung tumors [26], for which a dose of 8,000 rads
optimally balanced efficacy with toxicity [27]. Memorial’s
physicists had to assist in determining an appropriate pre-
scription dose when 125I was introduced. With a half-life of
almost 60 days, an 125I implant clearly must deliver a high-
er dose than a 222Rn (half-life of 3.8 days) implant. Lung tu-
mor implants with 125I delivering 16,000 rads were found
to be as effective as 222Rn implants delivering 8,000 rads [27],
so a conversion factor of 2 was empirically derived [28, 29].
The same prescription dose (160 Gy) was employed when
open 125I prostate implants were instituted at Memorial in
1970 [30].
Danish urologist Hans Henrik Holm adopted the 160 Gy
dose when he introduced ultrasound-guided transperineal
PB in the early 1980’s [31], as did Haakon Ragde and John
Blasko when they brought the procedure to the United States
of America [32]. This dose was reduced by 10% (to 144 Gy)
in 1999, based upon the exclusion of titanium K-edge cha -
racteristic X-rays from low-energy air-kerma strength cal-
ibrations [18, 33, 34].
But is a prescription dose derived from the treatment of
lung tumors with 222Rn appropriate for treating prostate can-
cer with 125I? Properly distributed, 144 Gy has been demon-
strated to be an effectivePB dose, but is it optimal? When Memo-
rial’s brachytherapists and physicists empirically adopted
a conversion factor of 2 to apply their clinical experience with
222Rn to dosing with 125I (without the benefit of radiobiological
calculations), they recognized that it was no more than‘an ed-
ucated guess and is subject to revision on the basis of further
experimental studies and clinical experience’ [28]. There are
indications that 144 Gy may not be optimal for prostate can-
cer [35], and even the historical dose used for permanent lung
brachytherapy required adjustment [36, 37]. Should all pro -
state cancers, regardless of bulk and grade, be treated to the
same dose? Henschke utilized a sliding scale based on implant
volume [28], and customized dosing has recently been pro-
posed [38]. Re-evaluation of the dose-response relationship
may define optimal dosing prescription, resulting in greater
efficacy or reduced toxicity. Perhaps the reason the brachyther-
apy community has not addressed this issue is that the rela-
tionship between dose and response is unclear [39]. This am-
biguity reflects the inadequacy of currently accepted dose
metrics (D90, V100) to adequately measure implant quality, only
single points on a given DVH. Metrics that are independent
of post-implant CT contouring subjectivity are needed to
mount meaningful multi-institutional trials.
Seed/beam sequencing
When Holm introduced the ultrasound-guided transper-
ineal PB in the early 1980’s, he prescribed a dose of 160 Gy
followed by 47.4 Gy in 20 fractions of EBRT. Rectal toxici-
ty was so high that he was forced to abandon the procedure
[40]. Although John Blasko appreciated the potential of the
combined-therapy approach, he was daunted by the toxi-
city that Holm’s patients had experienced and prudently
altered the prescription [41]. Lower grade/stage tumors
were treated with implant monotherapy; more aggressive
or advanced tumors received combined therapy, but the im-
plant prescription dose was reduced to 120 Gy. He was also
concerned about the dose intensity of concurrent implant
and EBRT, so he also altered the sequencing. EBRT (45 Gy
over 5 weeks) was delivered first, and the implant was per-
formed one month later.
There are potential advantages to preserving Holm’s orig-
inal sequencing. Although physicists prepare an optimal im-
plant plan, brachytherapists do not always achieve it. There
is often underdosing due to an unanticipated degree of 
tissue elasticity, glandular swelling, and seed migration. 
By delivering EBRT first, the opportunity is lost to com-
pensate for a suboptimal implant. Reversing the order by
implanting before EBRT may be beneficial where dose-paint-
ing, achievable with intensity-modulated EBRT, can com-
plement the implant dose distribution. Use of short half-life
radio nuclides (103Pd and 131Cs at 17 and 9.7 days, respec-
tively) reduces concern regarding concurrent EBRT dosing
since > 90% of the brachytherapy dose is delivered after 
8 weeks. However, the optimal role of each radionuclide has
not been determined, nor has this question been asked in
a randomized, multi-institutional, prospective study [42, 43].
Technique traits
Haakon Ragde’s ultrasound unit was monophasic when
he and John Blasko performed their first PB implant 1985 (John
Blasko, personal communication, 2011). By necessity, they re-
lied on ruler measurements to determine depth of needle in-
sertion; miscalculation could result in inadequate coverage
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of the base of the gland, or placement of seeds in the bladder
or penile bulb [44]. Although biphasic ultrasound units (with
sagittal imaging that allowed direct measurement of insertion
depth) were soon introduced, the ‘Seattle technique’ did not
reflect this capability for a decade [45]. Hundreds of bra -
chytherapists travelled to Seattle in the 1990’s to learn the pro-
cedure; the technique they acquired did not utilize sagittal im-
aging. It is likely that many prostate brachytherapists still do
not fully exploit the capabilities of their equipment.
Other vestigial prostate brachytherapy practices include:
a) source calibrations based on air-kerma strength [34],
b) post-implant assessment based upon CT scanning 
30 days after the implant rather than at a time that reflects
the temporal resolution of edema and the radionuclide’s
half-life [46],
c) selection of radionuclide by convention rather than by
a methodical multi-institutional study, and
d) treatment planning based on dose calculations to water
instead of the tissue of interest [47].
Conclusions
Evolutionary biologists have demonstrated that orga -
nisms retain superfluous behavioral and structural traits that
reflect their evolution. These features are not beneficial and
may even be detrimental. Similarly, vestigial features per-
sist in medical procedures. Although PB has been demon-
strated to be an effective treatment modality, reappraisal of
time-honored conventions is warranted. If we rely on dog-
ma rather than intelligent design, PB will struggle for sur-
vival in the face of competing technologies.
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